Arteris, Inc. (Nasdaq: AIP), a leading provider of system IP which
accelerates system-on-chip (SoC) creation, today announced
financial results for the fourth quarter and year ended
December 31, 2024 and provided first quarter and full year
2025 guidance.
“In the fourth quarter of 2024, we achieved a
record Annual Contract Value plus royalties of $65.1 million,
driven by strong demand for our commercial semiconductor System IP
products, particularly in AI-driven enterprise computing and
automotive SoCs,” said K. Charles Janac, President and CEO of
Arteris. “As AI adoption accelerates across data centers,
autonomous driving, and edge devices, the growing complexity of
both high performance and traditional technologies like MCUs is
fueling demand for the efficiency enabled by Arteris’
networks-on-chip IP technology, contributing to new customer wins,
and expanded partnerships. With a robust product pipeline and
deepening relationships with top-tier technology companies, we
believe we are well-positioned to capitalize on exciting
high-growth opportunities including Generative AI and Autonomous
Driving,” concluded Janac.
Fourth Quarter 2024 Financial
Highlights:
- Revenue of $15.5
million, up 24% year-over-year
- Annual Contract
Value (ACV) plus royalties of $65.1 million, up 16%
year-over-year, growing to the highest level we have ever
reported
- Remaining
performance obligation (RPO) of $88.4 million, up 22%
year-over-year, growing to the highest level we have ever
reported
- Operating loss of
$7.1 million, compared to an operating loss of
$9.2 million in the fourth quarter of 2023
- Non-GAAP operating
loss of $2.8 million, compared to a Non-GAAP operating loss of
$5.5 million in the fourth quarter of 2023
- Net loss of
$8.2 million or $0.20 per share
- Non-GAAP net loss
of $3.9 million or $0.10 per share
Full year 2024 Financial Highlights:
- Revenue of
$57.7 million, up 8% year-over-year
- Operating loss of
$31.6 million, compared to an operating loss of
$35.1 million for the year-ended 2023
- Non-GAAP operating
loss of $14.8 million, compared to a Non-GAAP operating loss
of $19.8 million for the year-ended 2023
- Net loss of
$33.6 million or $0.86 per share
- Non-GAAP net loss
of $16.9 million or $0.43 per share
Fourth Quarter 2024 Business Highlights:
- 2024 was a strong
year for Arteris, seeing accelerating demand for commercial system
IP. We signed on 14 new customers, including two major automotive
OEMs, and increased our footprint in key technology areas, such as
chiplets, microcontrollers (MCUs), and AI;
- Record high $65.1
million in ACV plus royalties, driven by the addition of new
customers as well as increased uptake by our current
customers;
- Large, established
customers are continuing to broaden their use of the Arteris
product portfolio, with a top 5 technology company licensing
Magillem and CSRCompiler, and a top 5 automotive semiconductor
company licensing several additional SoC designs;
- Delivered on last
quarter’s strategic expansion into the microcontroller space,
licensing Arteris interconnect to Infineon, the leading MCU
company, serving the world’s top automotive Tier 1 vendors and
OEMs;
- Announced design
wins with GigaDevice for automotive microcontrollers, and Menta for
edge AI and IoT chiplet designs; and
- Announced the
release of FlexGen smart NoC IP, which has the potential to deliver
up to 10x engineer productivity and lower power consumption,
through the automation of NoC design creation.
Non-GAAP gross profit, Non-GAAP gross margin,
Non-GAAP operating loss, Non-GAAP operating loss margin, Non-GAAP
net loss, Non-GAAP net loss per share, free cash flow and free cash
flow margin are Non-GAAP financial measures. Additional information
on Arteris’ historic reported results, including a reconciliation
of these Non-GAAP financial measures to their most comparable GAAP
measures, is included in the financial tables below.
First Quarter and Full Year 2025
Guidance:
|
Q1 2025 |
FY 2025 |
|
(in millions) |
ACV +
royalties |
$65.5 - $67.5 |
$73.0 - $77.0 |
Revenue |
$15.7 - $16.1 |
$66.0 - $70.0 |
Non-GAAP operating
loss |
$3.0 - $4.0 |
$8.5 - $12.5 |
Free cash
flow |
$(2.0) - $2.0 |
$1.0 - $7.0 |
|
|
|
The guidance provided above are forward-looking
statements and reflects Arteris' expectations as of today's date.
Actual results may differ materially. Refer to the section titled
"Forward-Looking Statements" below for information on the factors,
among others, that could cause our actual results to differ
materially from these forward-looking statements.
A reconciliation of Non-GAAP guidance measures
reported above to corresponding GAAP measures is not available on a
forward-looking basis without unreasonable effort due to the
uncertainty of expenses that may be incurred in the future,
although it is important to note that these factors could be
material to Arteris' results computed in accordance with GAAP.
Definitions of the other business metrics used
in this press release including ACV, active customers, confirmed
design starts and RPO are included below under the heading “Other
Business Metrics.”
Conference Call
Arteris will host a conference call today on
February 18, 2025 to review its fourth quarter and full year 2024
financial results and to discuss its financial outlook.
Time: |
4:30PM ET |
United States/Canada Toll
Free: |
1-646-307-1865 |
International Toll: |
1-800-717-1738 |
|
|
A live webcast will also be available in the
Investor Relations section of Arteris’ website at:
https://ir.arteris.com/events-and-presentations
A replay of the webcast will be available in the
Investor Relations section of Arteris' website approximately two
hours after the conclusion of the call and remain available for
approximately 30 calendar days.
About Arteris
Arteris is a leading provider of system IP for
the acceleration of system-on-chip (SoC) development across today’s
electronic systems. Arteris network-on-chip (NoC) interconnect IP
and SoC integration automation technology enable higher product
performance with lower power consumption and faster time to market,
delivering better SoC economics so its customers can focus on
dreaming up what comes next. Learn more at arteris.com.
© 2004-2025 Arteris, Inc. All rights reserved
worldwide. Arteris, Arteris IP, the Arteris IP logo, and the other
Arteris marks found at https://www.arteris.com/trademarks are
trademarks or registered trademarks of Arteris, Inc. or its
subsidiaries. All other trademarks are the property of their
respective owners.
Investor Contacts:ArterisNick HawkinsChief
Financial OfficerIR@arteris.com
Sapphire Investor Relations, LLCErica Mannion and Michael
Funari+1 617 542 6180IR@arteris.com
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995, as amended, including but not limited to,
statements regarding our future financial and operating
performance, including our GAAP and Non-GAAP guidance for the
fourth quarter and full year 2024 and first quarter and full year
2025; our market opportunity and its potential growth; our ability
to execute on existing customer contracts and drive increased
customer adoption of our system IP; and our position within the
market and our ability to drive customer value. The words such as
"may," "will," "could," "expect," "approximately," "believe,"
"estimate," "future," "potential," "guidance," "outlook," and
similar words or expressions are intended to identify
forward-looking statements, although not all forward-looking
statements contain these identifying words. Any forward-looking
statements contained herein are based on our historical performance
and our current plans, estimates and expectations and are not a
representation that such plans, estimates, or expectations will be
achieved. These forward-looking statements represent our
expectations as of the date of this press release. Subsequent
events may cause these expectations to change, and we disclaim any
obligation to update the forward-looking statements in the future,
except as required by law. These forward-looking statements are
subject to known and unknown risks and uncertainties that may cause
actual results to differ materially from our current expectations.
Important factors that could cause actual results to differ
materially from those anticipated in our forward-looking statements
include, but are not limited to, the significant competition we
face from larger companies and third-party providers; our history
of net losses; whether semiconductor companies in the automotive
market, enterprise computing market, communications market,
consumer electronics market, and industrial markets incorporate our
solutions into their end products and the growth and economic
stability of these end markets; our ability to attract new
customers and the extent to which our customers renew their
subscriptions for our solutions; the ability of our customers’ end
products achieving market acceptance or growth; our ability to
sustain or grow our licensing revenue; our ability, and the cost,
to successfully execute on research and development efforts; the
occurrence of product errors or defects in our solutions; if we
fail to offer high-quality support; the occurrence of
macro-economic conditions that adversely impact us, our customers
and their end product markets; the effects of geopolitical
conflicts, such as the military conflict between Russia and
Ukraine; the range of regulatory, operational, financial and
political risks we are exposed to as a result of our dependence on
international customers and operations; our ability to protect our
proprietary technology and inventions through patents and other IP
rights; whether we are subject to any liabilities or fines as a
result of government regulation, including import, export and
economic sanctions laws and regulations; the occurrence of a
disruption in our networks or a security breach; risks associated
with doing business in China, including as a result of changes to
trade relations between the U.S. and China; and the other factors
described under the heading “Risk Factors” in our Annual Report on
Form 10-K for the year ended December 31, 2024 to be filed with the
Securities and Exchange Commission (SEC) on or about February 18,
2025. All forward-looking statements reflect our beliefs and
assumptions only as of the date of this press release. We undertake
no obligation to update forward-looking statements to reflect
future events or circumstances. Our results for the quarter and
year ended December 31, 2024 are not necessarily indicative of our
operating results for any future periods.
Arteris, Inc. |
Condensed Consolidated Statements of
Operations |
(In thousands, except share and per share data) |
(Unaudited) |
|
|
Three Months Ended December 31, |
|
Twelve Months Ended December 31, |
|
2024 |
|
2023 |
|
2024 |
|
2023 |
Revenue |
|
|
|
|
|
|
|
Licensing, support and maintenance |
$ |
14,016 |
|
|
$ |
11,347 |
|
|
$ |
52,815 |
|
|
$ |
48,273 |
|
Variable royalties and other |
|
1,473 |
|
|
|
1,157 |
|
|
|
4,909 |
|
|
|
5,393 |
|
Total revenue |
|
15,489 |
|
|
|
12,504 |
|
|
|
57,724 |
|
|
|
53,666 |
|
Cost of revenue |
|
1,575 |
|
|
|
1,448 |
|
|
|
5,962 |
|
|
|
5,077 |
|
Gross profit |
|
13,914 |
|
|
|
11,056 |
|
|
|
51,762 |
|
|
|
48,589 |
|
Operating expenses: |
|
|
|
|
|
|
|
Research and development |
|
11,532 |
|
|
|
10,663 |
|
|
|
45,007 |
|
|
|
45,128 |
|
Sales and marketing |
|
5,365 |
|
|
|
5,029 |
|
|
|
20,796 |
|
|
|
20,659 |
|
General and administrative |
|
4,119 |
|
|
|
4,613 |
|
|
|
17,555 |
|
|
|
17,944 |
|
Total operating expenses |
|
21,016 |
|
|
|
20,305 |
|
|
|
83,358 |
|
|
|
83,731 |
|
Loss from operations |
|
(7,102 |
) |
|
|
(9,249 |
) |
|
|
(31,596 |
) |
|
|
(35,142 |
) |
Interest expense |
|
(45 |
) |
|
|
(75 |
) |
|
|
(244 |
) |
|
|
(211 |
) |
Other income (expense),
net |
|
824 |
|
|
|
917 |
|
|
|
3,400 |
|
|
|
3,558 |
|
Loss before income taxes and
loss from equity method investment |
|
(6,323 |
) |
|
|
(8,407 |
) |
|
|
(28,440 |
) |
|
|
(31,795 |
) |
Loss from equity method
investment, net of tax |
|
634 |
|
|
|
910 |
|
|
|
2,698 |
|
|
|
3,397 |
|
Provision for income
taxes |
|
1,247 |
|
|
|
1,224 |
|
|
|
2,500 |
|
|
|
1,677 |
|
Net loss |
$ |
(8,204 |
) |
|
$ |
(10,541 |
) |
|
$ |
(33,638 |
) |
|
$ |
(36,869 |
) |
|
|
|
|
|
|
|
|
Net loss per share
attributable to common stockholders, basic and diluted |
$ |
(0.20 |
) |
|
$ |
(0.29 |
) |
|
$ |
(0.86 |
) |
|
$ |
(1.03 |
) |
Weighted average shares used
in computing per share amounts, basic and diluted |
|
40,157,199 |
|
|
|
36,816,597 |
|
|
|
38,914,197 |
|
|
|
35,675,689 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Arteris, Inc. |
Condensed Consolidated Balance Sheets |
(In thousands, except share and per share data) |
|
|
As of December 31, |
|
2024 |
|
2023 |
ASSETS |
|
|
|
Current assets: |
|
|
|
Cash and cash equivalents |
$ |
13,684 |
|
|
$ |
13,696 |
|
Short-term investments |
|
30,157 |
|
|
|
27,477 |
|
Accounts receivable, net
of allowance of $131 and $93 as of December 31, 2024, and
2023, respectively |
|
20,608 |
|
|
|
12,003 |
|
Prepaid expenses and other
current assets |
|
4,634 |
|
|
|
5,254 |
|
Total current assets |
|
69,083 |
|
|
|
58,430 |
|
Property and equipment,
net |
|
4,019 |
|
|
|
5,745 |
|
Long-term investments |
|
8,504 |
|
|
|
11,802 |
|
Equity method investment |
|
5,802 |
|
|
|
8,500 |
|
Operating
lease right-of-use assets |
|
3,838 |
|
|
|
4,289 |
|
Intangibles, net |
|
3,024 |
|
|
|
3,858 |
|
Goodwill |
|
4,178 |
|
|
|
4,178 |
|
Other assets |
|
7,687 |
|
|
|
5,999 |
|
TOTAL ASSETS |
$ |
106,135 |
|
|
$ |
102,801 |
|
LIABILITIES AND
STOCKHOLDERS’ EQUITY |
|
|
|
Current liabilities: |
|
|
|
Accounts payable |
$ |
539 |
|
|
$ |
183 |
|
Accrued expenses and other
current liabilities |
|
15,899 |
|
|
|
11,831 |
|
Operating lease liabilities,
current |
|
917 |
|
|
|
781 |
|
Deferred revenue, current |
|
40,445 |
|
|
|
31,537 |
|
Vendor financing arrangements,
current |
|
1,482 |
|
|
|
2,070 |
|
Total current liabilities |
|
59,282 |
|
|
|
46,402 |
|
Deferred revenue,
noncurrent |
|
35,177 |
|
|
|
25,172 |
|
Operating lease liabilities,
noncurrent |
|
2,998 |
|
|
|
3,610 |
|
Vendor financing arrangements,
noncurrent |
|
594 |
|
|
|
1,292 |
|
Deferred income,
noncurrent |
|
7,631 |
|
|
|
8,810 |
|
Other liabilities |
|
1,641 |
|
|
|
2,412 |
|
Total liabilities |
|
107,323 |
|
|
|
87,698 |
|
Stockholders’ (deficit)
equity: |
|
|
|
Preferred stock, par value of $0.001—10,000,000 shares authorized
and no shares issued and outstanding as of both December 31,
2024, and 2023 |
|
— |
|
|
|
— |
|
Common stock, par value of $0.001—300,000,000 shares authorized at
December 31, 2024, and 2023; 40,724,936 and 37,518,583 shares
issued and outstanding at December 31, 2024, and 2023,
respectively |
|
40 |
|
|
|
37 |
|
Additional paid-in capital |
|
135,522 |
|
|
|
118,193 |
|
Accumulated other
comprehensive income |
|
135 |
|
|
|
120 |
|
Accumulated deficit |
|
(136,885 |
) |
|
|
(103,247 |
) |
Total stockholders’ (deficit) equity |
|
(1,188 |
) |
|
|
15,103 |
|
TOTAL LIABILITIES AND
STOCKHOLDERS’ EQUITY |
$ |
106,135 |
|
|
$ |
102,801 |
|
|
|
|
|
|
|
|
|
Arteris, Inc. |
Condensed Consolidated Statements of Cash
Flows |
(In thousands) |
|
|
Twelve Months EndedDecember 31, |
|
2024 |
|
2023 |
CASH FLOWS FROM OPERATING
ACTIVITIES: |
|
|
|
Net loss |
$ |
(33,638 |
) |
|
$ |
(36,869 |
) |
Adjustments to reconcile net loss to net cash used in operating
activities: |
|
|
|
Depreciation and amortization |
|
3,362 |
|
|
|
3,069 |
|
Stock-based compensation |
|
15,938 |
|
|
|
14,535 |
|
Pension plan expenses |
|
163 |
|
|
|
134 |
|
Amortization of deferred income |
|
(1,182 |
) |
|
|
(1,179 |
) |
Loss from equity method investment |
|
2,698 |
|
|
|
3,397 |
|
Net accretion of discounts on available-for-sale securities |
|
(695 |
) |
|
|
(893 |
) |
Other, net |
|
(9 |
) |
|
|
128 |
|
Changes in operating assets and liabilities: |
|
|
|
Accounts receivable, net |
|
(8,605 |
) |
|
|
(4,858 |
) |
Prepaid expenses and other assets |
|
(1,068 |
) |
|
|
(1,301 |
) |
Accounts payable |
|
324 |
|
|
|
(389 |
) |
Accrued expenses and other liabilities |
|
3,079 |
|
|
|
2,467 |
|
Deferred revenue |
|
18,913 |
|
|
|
6,030 |
|
Net cash used in operating activities |
|
(720 |
) |
|
|
(15,729 |
) |
CASH FLOWS FROM INVESTING
ACTIVITIES: |
|
|
|
Purchases of property and
equipment |
|
(324 |
) |
|
|
(1,503 |
) |
Purchases of
available-for-sale securities and other |
|
(37,175 |
) |
|
|
(47,788 |
) |
Proceeds from maturities of
available-for-sale securities and other |
|
38,469 |
|
|
|
44,650 |
|
Other investing
activities |
|
— |
|
|
|
(50 |
) |
Net cash provided by (used in) investing activities |
|
970 |
|
|
|
(4,691 |
) |
CASH FLOWS FROM FINANCING
ACTIVITIES: |
|
|
|
Payments of contingent
consideration for business combination |
|
— |
|
|
|
(1,592 |
) |
Principal payments under
vendor financing arrangements |
|
(1,749 |
) |
|
|
(1,289 |
) |
Payments to tax authorities
for shares withheld from employees |
|
— |
|
|
|
(607 |
) |
Proceeds from exercise of
stock options |
|
890 |
|
|
|
490 |
|
Proceeds from employee stock
purchase plan |
|
538 |
|
|
|
— |
|
Other financing
activities |
|
59 |
|
|
|
79 |
|
Net cash used in financing activities |
|
(262 |
) |
|
|
(2,919 |
) |
NET DECREASE IN CASH, CASH
EQUIVALENTS AND RESTRICTED CASH |
|
(12 |
) |
|
|
(23,339 |
) |
CASH, CASH EQUIVALENTS AND
RESTRICTED CASH, beginning of period |
|
14,084 |
|
|
|
37,423 |
|
CASH, CASH EQUIVALENTS AND
RESTRICTED CASH, end of period |
$ |
14,072 |
|
|
$ |
14,084 |
|
|
|
|
|
|
|
|
|
Non-GAAP Financial Measures
To supplement our financial results, which are
prepared and presented in accordance with GAAP, we use certain
non-GAAP financial measures, as described below, to understand and
evaluate our core performance. These non-GAAP measures, which may
be different than similarly-titled measures used by other
companies, are presented to enhance investors’ overall
understanding of our financial performance and should not be
considered a substitute for, or superior to, the financial
information prepared and presented in accordance with GAAP.
We define "Non-GAAP gross profit and Non-GAAP
gross margin" as GAAP gross profit and GAAP gross margin, adjusted
for stock-based compensation expense and amortization of intangible
assets included in cost of revenue. We define “Non-GAAP Loss from
Operations” as our income (loss) from operations adjusted to
exclude stock-based compensation, acquisition costs and
amortization of acquired intangible assets. We define “Non-GAAP Net
Loss” as our net income (loss) adjusted to exclude stock-based
compensation and amortization of acquired intangible assets.
We define “Non-GAAP EPS”, as our Non-GAAP Net
Income (Loss) divided by our GAAP weighted-average number of shares
outstanding for the period on a diluted basis. Management uses
Non-GAAP EPS to evaluate the performance of our business on a
comparable basis from period to period.
The above items are excluded from our Non-GAAP
Gross Profit, Non-GAAP Income (Loss) from Operations and Non-GAAP
Net Income (Loss) because these items are non-cash in nature, or
are not indicative of our core operating performance, and render
comparisons with prior periods and competitors less meaningful. We
believe Non-GAAP Gross Profit, Non-GAAP Income (Loss) from
Operations and Non-GAAP Net Income (Loss) provide useful
supplemental information to investors and others in understanding
and evaluating our results of operations, as well as provide a
useful measure for period-to-period comparisons of our business
performance.
We define free cash flow as net cash used in
operating activities less cash used for purchases of property and
equipment. We believe that free cash flow is a useful indicator of
liquidity that provides information to management and investors,
even if negative, about the amount of cash used in our operations
other than that used for investments in property and equipment.
Other Business Metrics
Active Customers – we define
Active Customers as customers who have entered into a license
agreement with us that remains in effect. The retention and
expansion of our relationships with existing customers are key
indicators of our revenue potential.
Annual Contract Value (ACV) –
we define Annual Contract Value for an individual customer
agreement as the total fixed fees under the agreement divided by
the number of years in the agreement term. Our total ACV is the
aggregate ACVs for all our customers as measured at a given point
in time. Total fixed fees includes licensing, support and
maintenance and other fixed fees under IP licensing or software
licensing agreements but excludes variable revenue derived from
licensing agreements with customers, particularly royalties. We
define ACV plus royalties as ACV plus the trailing-twelve-months
variable royalties and other revenue.
Confirmed Design Starts – we
define Confirmed Design Starts as when customers confirm their
commencement of new semiconductor designs using our interconnect IP
and notify us. Confirmed Design Starts is a metric management uses
to assess the activity level of our customers in terms of the
number of new semiconductor designs that are started using our
interconnect IP in a given period. We believe that the number of
Confirmed Design Starts is an important indicator of the growth of
our business and future royalty revenue trends.
Remaining Performance Obligations (RPO)
– we define Remaining Performance Obligations as the
amount of contracted future revenue that has not yet been
recognized, including deferred revenue, billed and unbilled
cancelable and non-cancelable contracted amounts.
Arteris,
Inc. |
Reconciliation of GAAP Measures to Non-GAAP
Measures |
(In thousands,
except share and per share data) |
(Unaudited) |
|
|
Three Months Ended December
31, |
|
Twelve Months Ended December
31, |
|
2024 |
|
2023 |
|
2024 |
|
2023 |
Gross profit |
$ |
13,914 |
|
|
$ |
11,056 |
|
|
$ |
51,762 |
|
|
$ |
48,589 |
|
Add: |
|
|
|
|
|
|
|
Stock-based compensation
expense included in cost of revenue |
|
187 |
|
|
|
170 |
|
|
|
783 |
|
|
|
556 |
|
Amortization of acquired
intangible assets (1) |
|
49 |
|
|
|
50 |
|
|
|
199 |
|
|
|
149 |
|
Non-GAAP gross profit |
$ |
14,150 |
|
|
$ |
11,276 |
|
|
$ |
52,744 |
|
|
$ |
49,294 |
|
Gross margin |
|
90 |
% |
|
|
88 |
% |
|
|
90 |
% |
|
|
91 |
% |
Non-GAAP gross margin |
|
91 |
% |
|
|
90 |
% |
|
|
91 |
% |
|
|
92 |
% |
|
|
|
|
|
|
|
|
Research and development |
$ |
11,532 |
|
|
$ |
10,663 |
|
|
$ |
45,007 |
|
|
$ |
45,128 |
|
Stock-based compensation
expense |
|
(1,959 |
) |
|
|
(1,668 |
) |
|
|
(7,509 |
) |
|
|
(7,324 |
) |
Amortization of acquired
intangible assets (1) |
|
(109 |
) |
|
|
(85 |
) |
|
|
(389 |
) |
|
|
(390 |
) |
Non-GAAP research and
development |
$ |
9,464 |
|
|
$ |
8,910 |
|
|
$ |
37,109 |
|
|
$ |
37,414 |
|
|
|
|
|
|
|
|
|
Sales and marketing |
$ |
5,365 |
|
|
$ |
5,029 |
|
|
$ |
20,796 |
|
|
$ |
20,659 |
|
Stock-based compensation
expense |
|
(849 |
) |
|
|
(624 |
) |
|
|
(3,079 |
) |
|
|
(2,712 |
) |
Amortization of acquired
intangible assets (1) |
|
(58 |
) |
|
|
(57 |
) |
|
|
(229 |
) |
|
|
(228 |
) |
Non-GAAP sales and
marketing |
$ |
4,458 |
|
|
$ |
4,348 |
|
|
$ |
17,488 |
|
|
$ |
17,719 |
|
|
|
|
|
|
|
|
|
General and
administrative |
$ |
4,119 |
|
|
$ |
4,613 |
|
|
$ |
17,555 |
|
|
$ |
17,944 |
|
Stock-based compensation
expense |
|
(1,136 |
) |
|
|
(1,092 |
) |
|
|
(4,567 |
) |
|
|
(3,943 |
) |
Non-GAAP general and
administrative |
$ |
2,983 |
|
|
$ |
3,521 |
|
|
$ |
12,988 |
|
|
$ |
14,001 |
|
|
|
|
|
|
|
|
|
Loss from operations |
$ |
(7,102 |
) |
|
$ |
(9,249 |
) |
|
$ |
(31,596 |
) |
|
$ |
(35,142 |
) |
Stock-based compensation
expense |
|
4,131 |
|
|
|
3,554 |
|
|
|
15,938 |
|
|
|
14,535 |
|
Amortization of acquired
intangible assets (1) |
|
216 |
|
|
|
192 |
|
|
|
817 |
|
|
|
767 |
|
Non-GAAP loss from
operations |
$ |
(2,755 |
) |
|
$ |
(5,503 |
) |
|
$ |
(14,841 |
) |
|
$ |
(19,840 |
) |
|
|
|
|
|
|
|
|
Net loss |
$ |
(8,204 |
) |
|
$ |
(10,541 |
) |
|
$ |
(33,638 |
) |
|
$ |
(36,869 |
) |
Stock-based compensation
expense |
|
4,131 |
|
|
|
3,554 |
|
|
|
15,938 |
|
|
|
14,535 |
|
Amortization of acquired
intangible assets (1) |
|
216 |
|
|
|
192 |
|
|
|
817 |
|
|
|
767 |
|
Non-GAAP net loss(2) |
$ |
(3,857 |
) |
|
$ |
(6,795 |
) |
|
$ |
(16,883 |
) |
|
$ |
(21,567 |
) |
|
|
|
|
|
|
|
|
Net loss per share
attributable to common stockholders, basic and diluted |
$ |
(0.20 |
) |
|
$ |
(0.29 |
) |
|
$ |
(0.86 |
) |
|
$ |
(1.03 |
) |
Per share impacts of
adjustments to net loss (3) |
$ |
0.10 |
|
|
$ |
0.11 |
|
|
$ |
0.43 |
|
|
$ |
0.43 |
|
Non-GAAP net loss per share
attributable to common stockholders, basic and diluted |
$ |
(0.10 |
) |
|
$ |
(0.18 |
) |
|
$ |
(0.43 |
) |
|
$ |
(0.60 |
) |
|
|
|
|
|
|
|
|
Weighted average shares used
in computing per share amounts, basic and diluted |
|
40,157,199 |
|
|
|
36,816,597 |
|
|
|
38,914,197 |
|
|
|
35,675,689 |
|
|
(1) Represents the amortization expenses of our
intangible assets attributable to our acquisitions. |
(2) Our GAAP tax provision is primarily related to
foreign withholding taxes and income tax in profitable foreign
jurisdictions. We maintain a full valuation allowance against our
deferred tax assets in the US. Accordingly, there is no significant
tax impact associated with these Non-GAAP adjustments. |
(3) Reflects the aggregate adjustments made to
reconcile Non-GAAP net loss to our net loss as noted in the above
table, divided by the GAAP diluted weighted average number of
shares of the relevant period. |
|
Free Cash Flow
|
Twelve Months EndedDecember 31, |
|
2024 |
|
2023 |
Net cash used in operating activities |
$ |
(720 |
) |
|
$ |
(15,729 |
) |
Less: |
|
|
|
Purchase of property and
equipment |
|
(324 |
) |
|
|
(1,503 |
) |
Free cash flow |
$ |
(1,044 |
) |
|
$ |
(17,232 |
) |
Net cash provided by (used in)
investing activities |
$ |
970 |
|
|
$ |
(4,691 |
) |
Net cash used in financing
activities |
$ |
(262 |
) |
|
$ |
(2,919 |
) |
Arteris (NASDAQ:AIP)
Historical Stock Chart
From Feb 2025 to Mar 2025
Arteris (NASDAQ:AIP)
Historical Stock Chart
From Mar 2024 to Mar 2025